86. Enbiosis Biotechnology: using AI to tackle the nation’s gut problems

Founder: Omer Ozkan, Ozkan Ufuk Nalbantoglu, and Aycan Gundogdu
Year founded: 2021
Website: enbiosis.com 

Personalised healthcare is a booming sector. AI is helping to further amplify the offering of startups who are filling the gaps in the healthcare market with innovative, tailored solutions.

Enbiosis is one such startup. Using AI technology and clinically proven methods, it has set out to create personalised diet solutions that can transform gut health; itself becoming an obsession with today’s consumers.

Our proudest achievement in the last financial year was the publication of our third multicenter clinical study in the American Journal of Gastroenterology, the leading journal in clinical gastroenterology

Cofounder Omer Ozkan’s lightbulb moment came when he realised that the significant impact the gut microbiome has on overall health and wellbeing wasn’t reflected in personalised recommendations or scientific validation. The team knew there had to be a better way to empower people with precise, effective health solutions.

Enbiosis’ strategy is to target the gut microbiome, which is linked to over 90% of chronic diseases. The business uses its AI-driven algorithm – that holistically evaluates the relationship between trillions of gut bacteria and general health parameters – to create bespoke food and supplement programmes that address the root causes of various chronic conditions.

And, unlike certain consumer brands seen on today’s supermarket shelves, Enbiosis is gaining approval from the experts. It’s targeting healthcare professionals such as gastroenterologists and dietitians who want science-backed alternatives to existing, aging treatments like the FODMAP diet.

The startup has secured investment from Pragma Corporate Finance and its global partnerships include US distributor, Evexia Diagnostics. It also has a partnership with Fullscript, one of the largest supplement distributors in the US.

“Our proudest achievement in the last financial year was the publication of our third multicentre clinical study in the American Journal of Gastroenterology, the leading journal in clinical gastroenterology,” says Ozkan. “This study proved that our personalised diet plan is superior to the low FODMAP diet, which is currently the gold standard for treating IBS patients.”

In five years, the team of cofounders envision Enbiosis as a global leader in personalised health solutions, recognised for its cutting-edge AI-driven microbiome technology.

Here at Startups, we’ve a gut feeling (sorry) that we’ll be seeing more from Enbiosis’ and its bespoke solutions for those with gut health problems in 2025 and beyond.